Beijing Konruns Pharmaceutical Co.,Ltd.

603590

CNE1000036K3

Pharmaceuticals

End-of-day quote Shanghai S.E. Other stock markets 23:00:00 16/05/2024 BST			5-day change	1st Jan Change
30.57 ^CNY	+1.33%		-4.26%	-19.72%

04-25	Beijing Konruns Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
04-08	Beijing Konruns Pharmaceutical Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Beijing Konruns Pharmaceutical Co.,Ltd. cancelled the transaction announced on March 1, 2021

July 14, 2022

On July 15, 2022, Beijing Konruns Pharmaceutical Co.,Ltd. cancelled the transaction. The cancelation was approved in the 27th meeting of the 3rd Board of Directors and the 24th meeting of the 3rd Board of Supervisors.

Latest news about Beijing Konruns Pharmaceutical Co.,Ltd.

Beijing Konruns Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	04-25	CI
Beijing Konruns Pharmaceutical Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	04-08	CI
Konruns Pharma Enrolls First Subject in Phase 3 Study of Cancer Drug	02-06	MT
Beijing Konruns Pharmaceutical Gets Nod to Test KC1036 Tablets as Esophagus Cancer Treatment	12-27	MT
Konruns Pharmaceutical Gets Clearance for Clinical Trial of Sarcoma Treatment	12-20	MT
Beijing Konruns Pharmaceutical Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	27/10/23	CI
Certain A Shares of Beijing Konruns Pharmaceutical Co.,Ltd. are subject to a Lock-Up Agreement Ending on 27-AUG-2023.	26/08/23	CI
Beijing Konruns Pharmaceutical Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	31/07/23	CI
Chengdu WestGene Biomedical Technology Co., Ltd. announced that it has received $63.25 million in funding from Qingdao Honline Huaxin Asset Management Co., Ltd., Beijing Konruns Pharmaceutical Co.,Ltd., Hangzhou Tigermed Consulting Co., Ltd, Chengdu Guanghua Wutong Equity Investment Fund Management Co., Ltd., Yingke Innovation Asset Management Co., Ltd.	19/06/23	CI
Beijing Konruns Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	25/04/23	CI
Chengdu WestGene Biomedical Technology Co., Ltd. announced that it has received $21.45 million in funding from Qingdao Honline Huaxin Asset Management Co., Ltd.,Yingke Innovation Asset Management Co., Ltd.,Chengdu Guanghua Wutong Equity Investment Fund Management Co., Ltd. and Hangzhou Tigermed Consulting Co., Ltd.	05/12/22	CI
Beijing Konruns Pharmaceutical Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	25/10/22	CI
Certain A Shares of Beijing Konruns Pharmaceutical Co.,Ltd. are subject to a Lock-Up Agreement Ending on 27-AUG-2022.	26/08/22	CI
Beijing Konruns Pharmaceutical Co.,Ltd. cancelled the transaction announced on March 1, 2021	14/07/22	CI
Beijing Konruns Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022	22/04/22	CI
Tranche Update on Beijing Konruns Pharmaceutical Co.,Ltd.'s Equity Buyback Plan announced on January 21, 2021.	19/01/22	CI
Beijing Konruns Pharmaceutical Co.,Ltd.'s Equity Buyback announced on January 21, 2021, has expired with 2,273,523 shares, representing 1.44% for CNY 79.31 million.	18/01/22	CI
Tranche Update on Beijing Konruns Pharmaceutical Co.,Ltd.'s Equity Buyback Plan announced on January 21, 2021.	04/01/22	CI
Beijing Konruns Pharmaceutical Co.,Ltd. completed the acquisition of 13.70% stake in Beijing Konruns Biotechnology Co., Ltd. from NT Pharma Pacific Company Limited.	03/11/21	CI
Beijing Konruns Pharmaceutical Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021	25/10/21	CI
Beijing Konruns Pharmaceutical Co.,Ltd. intends to acquire 13.70% stake in Beijing Konruns Biotechnology Co., Ltd. from NT Pharma Pacific Company Limited for approximately CNY 130 million.	11/10/21	CI
Certain A Shares of Beijing Konruns Pharmaceutical Co.,Ltd. are subject to a Lock-Up Agreement Ending on 27-AUG-2021.	26/08/21	CI
Beijing Konruns Pharmaceutical Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2021	23/08/21	CI
Tranche Update on Beijing Konruns Pharmaceutical Co.,Ltd.'s Equity Buyback Plan announced on January 21, 2021.	01/07/21	CI
Beijing Konruns Pharmaceutical Co.,Ltd.(XSSC:603590) dropped from S&P Global BMI Index	21/06/21	CI

Chart Beijing Konruns Pharmaceutical Co.,Ltd.

Duration

Period

Chart Beijing Konruns Pharmaceutical Co.,Ltd.

More charts

Company Profile

Beijing Konruns Pharmaceutical Co., Ltd. is a China-based company principally engaged in the research and development, production and sales of drugs. The Company's main product Suling belongs to the haemocoagulase drug that activates the coagulation process, which is mainly used for hemostasis of superficial wound bleeding in surgical operations as well as the bleeding caused by postoperative, trauma and disease. The Companyâs present products under research include a range of innovative and generic drugs for tumors and blood. The Company mainly distributes its products in the domestic market.

Sector

Pharmaceuticals

Calendar

29/07/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Beijing Konruns Pharmaceutical Co.,Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

30.57 CNY

Average target price

44 CNY

Spread / Average Target

+43.93%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
BEIJING KONRUNS PHARMACEUTICAL CO.,LTD.	-19.72%	664M
ELI LILLY AND COMPANY	+32.29%	694B
NOVO NORDISK A/S	+29.39%	593B
JOHNSON & JOHNSON	-1.58%	371B
MERCK & CO., INC.	+19.94%	331B
ABBVIE INC.	+7.29%	290B
ASTRAZENECA PLC	+14.25%	239B
ROCHE HOLDING AG	-3.03%	209B
NOVARTIS AG	+10.02%	209B
AMGEN INC.	+8.73%	169B

Other Pharmaceuticals